Patent application number | Description | Published |
20100068285 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 03-18-2010 |
20100069426 | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer. | 03-18-2010 |
20100104655 | Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer. | 04-29-2010 |
20100216804 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 08-26-2010 |
20110217377 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 09-08-2011 |
20110275704 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 11-10-2011 |
20110294717 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers - The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles. | 12-01-2011 |
20120027820 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 02-02-2012 |
20120140790 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Termperature or High Molecular Weight Copolymers - The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles. | 06-07-2012 |
20120276162 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 11-01-2012 |
20120288541 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 11-15-2012 |
20130034608 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 02-07-2013 |
20130189315 | Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer. | 07-25-2013 |
20130230567 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 09-05-2013 |
20130236500 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 09-12-2013 |
20130243863 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 09-19-2013 |
20130280339 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic)acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 10-24-2013 |
20130295183 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 11-07-2013 |
20130295191 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 11-07-2013 |
20130302432 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 11-14-2013 |
20130344158 | Therapeutic Polymeric Nanoparticles with mTOR Inhibitors and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer. | 12-26-2013 |
20140030351 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers - The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles. | 01-30-2014 |
20140093579 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 04-03-2014 |
20140178475 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles. | 06-26-2014 |
20140186452 | Process for Preparing Therapeutic Nanoparticles - The present disclosure generally relates to a process for preparing therapeutic nanoparticles, where the process includes combining a therapeutic agent with an organic acid. The therapeutic nanoparticles may have, for example, improved drug loading and/or drug release properties. | 07-03-2014 |
20140186453 | Therapeutic Polymeric Nanoparticles with mTOR Inhibitors and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer. | 07-03-2014 |
20140248358 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles. | 09-04-2014 |
20140249158 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles. | 09-04-2014 |
20150017245 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES - The present disclosure relates in part to methods of treating cholangiocarcinoma or tonsillar cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles. | 01-15-2015 |
20150283081 | STABLE FORMULATIONS FOR LYOPHILIZING THERAPEUTIC PARTICLES - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 10-08-2015 |
20160045608 | LONG CIRCULATING NANOPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 02-18-2016 |
Patent application number | Description | Published |
20090012356 | ENDOSCOPIC DELIVERY DEVICES AND METHODS - Disclosed herein are various devices and methods that can be utilized independently or in conjunction with each other for endoscopic delivery of a wide ranges of medical devices, such as, for example, an endoscopic gastrointestinal bypass sleeve with an attachment cuff. Components of the system can include a space-creating device; an expandable fastener system with flower petal-shaped retention elements; and an endoscopic curved needle driver system. | 01-08-2009 |
20090012541 | EXPANDABLE FASTENER SYSTEM WITH FLOWER PETAL-SHAPED RETENTION ELEMENTS - Disclosed herein are various devices and methods that can be utilized independently or in conjunction with each other for endoscopic delivery of a wide ranges of medical devices, such as, for example, an endoscopic gastrointestinal bypass sleeve with an attachment cuff. Three primary components of the system include a space-creating device; an expandable fastener system with flower petal-shaped retention elements; and an endoscopic curved needle driver system. | 01-08-2009 |
20090012544 | GASTROINTESTINAL BYPASS SLEEVE AS AN ADJUNCT TO BARIATRIC SURGERY - Disclosed herein are systems and methods for treating a patient that has undergone a bariatric surgical procedure, to promote weight loss in the patient. The systems and methods can involve positioning a gastrointestinal bypass sleeve within a portion of the altered GI anatomy to create or restore a restriction, and/or create a malabsorptive effect via a gastric and partial intestinal bypass. The bypass sleeve can include a proximal attachment element for attaching the proximal end of the sleeve in a penetrating or non-penetrating manner at the gastroesophageal junction, stomach, neo-stomach, or other locations. The bypass can be placed during the same operative session as the bariatric surgical procedure, or alternatively at a later date. | 01-08-2009 |
20090012553 | METHODS AND DEVICES FOR INTRAGASTRIC SUPPORT OF FUNCTIONAL OR PROSTHETIC GASTROINTESTINAL DEVICES - Disclosed herein are systems and methods for attaching or maintaining the position of a therapeutic or diagnostic device in a body lumen, such as the GI tract without necessarily requiring any penetrating attachments through any body walls. The system can include at least two elements: a proximal orientation element and a distal support element. The proximal orientation element can be configured to reside at least partially within the esophageal lumen and the distal support element can be configured to reside in the stomach, such as along the greater curve of the stomach. An intragastric support system can have a first configuration in which the long axis of the proximal orientation element is substantially parallel and/or substantially coaxial with the long axis of the distal support element, and a second configuration in which the long axis of the proximal orientation element is not substantially coaxial with the long axis of the distal support element. The second configuration can thus advantageously retain the intragastric support system in place and prevent unwanted proximal migration of the distal support element into the esophagus or distal migration into the intestine. | 01-08-2009 |
20120232459 | DEVICES AND METHODS FOR ENDOLUMENAL GASTROINTESTINAL BYPASS - The present invention provides devices and methods for attachment of an endolumenal gastrointestinal device, such as an artificial stoma device, a gastrointestinal bypass sleeve or other therapeutic or diagnostic device, within a patient's digestive tract. In one application of the invention, an endolumenal bypass sleeve is removably attached in the vicinity of the gastroesophageal junction to treat obesity and/or its comorbidities, such as diabetes. The bypass sleeve may be at least partially deployed by eversion. | 09-13-2012 |
20120296254 | METHODS AND DEVICES FOR INTRAGASTRIC SUPPORT OF FUNCTIONAL OR PROSTHETIC GASTROINTESTINAL DEVICES - Disclosed herein are systems and methods for attaching or maintaining the position of a therapeutic or diagnostic device in a body lumen, such as the GI tract without necessarily requiring any penetrating attachments through any body walls. The system can include at least two elements: a proximal orientation element and a distal support element. The proximal orientation element can be configured to reside at least partially within the esophageal lumen and the distal support element can be configured to reside in the stomach, such as along the greater curve of the stomach. | 11-22-2012 |
20130331759 | DEVICES AND METHODS FOR GASTROINTESTINAL BYPASS - Devices and methods for gastrointestinal bypass are described. A gastrointestinal bypass device includes a gastrointestinal cuff and a gastrointestinal sleeve. The cuff may be configured to be attached in the esophagus, and may be sufficiently flexible to expand and collapse to conform with the inside of the esophagus to allow the esophagus to function substantially normally. The sleeve is configured to be coupled to the cuff, and may be made of a material that is floppy or flaccid but does not substantially expand radially. | 12-12-2013 |
20140358065 | METHODS FOR TOPOSCOPIC SLEEVE DELIVERY - Disclosed herein are elongate flexible medical devices which are capable of axial elongation through the mechanism of eversion or toposcopic expansion. In general, this may be accomplished by providing a flexible tubular device having a proximal end and a distal end. Retraction of the distal end in a proximal direction through the tubular body inverts the tube upon itself, causing an axial shortening of the overall length of the device. The original length of the device can be restored by coupling a pressurized media to the proximal end of the sleeve. If the distal end of the sleeve is temporarily restricted or closed, the pressurized media causes the distal end of the sleeve to travel distally until the full length of the sleeve has been restored. | 12-04-2014 |